Physician profile
John R Waldron
NPI 1154356343
$2,518.17
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $597 · 2021: $912 · 2022: $14.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $436.83 | 2019-2021 | |
| Amgen INC. | $250.95 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $240.84 | 2019-2021 | |
| Lilly USA, LLC | $190.98 | 2019-2021 | |
| Pfizer INC. | $178.53 | 2019-2021 | |
| Abbvie INC. | $152.49 | 2020-2022 | |
| Amarin Pharma, INC. | $129.49 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.83 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $104.33 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $81.85 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $78.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $69.11 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.94 | 2019-2021 | |
| Novo Nordisk INC | $52.23 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $46.10 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $28.16 | 2020 | |
| Eisai INC. | $27.30 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $26.87 | 2021 | |
| Bausch Health US, LLC | $26.86 | 2020 | |
| Astellas Pharma US INC | $26.81 | 2019 | |
| Allergan, INC. | $26.62 | 2020 | |
| Aytu Biopharma, INC. | $26.54 | 2019-2020 | |
| Sanofi Pasteur INC. | $23.09 | 2019 | |
| Emd Serono, INC. | $15.66 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.93 | 2021 | |
| Clarus Therapeutics INC. | $14.92 | 2021 | |
| Melinta Therapeutics, LLC | $14.74 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.78 | 2019 | |
| Genentech USA, INC. | $13.14 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Waldron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.